Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib

Japanese Journal of Clinical Oncology

Volumn 46, Issue 2, 2016, Pages 170-173

  Miyamoto, Shingo ^a   Ikushima, Soichiro ^a   Ono, Ryu ^a   Awano, Nobuyasu ^a   Kondo, Keisuke ^a   Furuhata, Yoshiaki ^a   Fukumoto, Kento ^a   Kumasaka, Toshio ^a  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

Acquired resistance; ALK positive lung cancer; Small cell lung cancer; Transformation

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; IRINOTECAN; NAVELBINE; PEMETREXED; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOPATHOLOGY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG METASTASIS; LYMPH NODE DISSECTION; MALIGNANT TRANSFORMATION; MEDIASTINUM LYMPH NODE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; SMALL CELL LUNG CANCER; TRANSBRONCHIAL ASPIRATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION; DRUG RESISTANCE; LUNG NEOPLASMS; LYMPH NODE; PATHOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SMALL CELL LUNG CARCINOMA;

EID: 84961595143     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyv173     Document Type: Article

References (6)

1. Isozaki H, Takigawa N, Kiura K. Mechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancer. Cancers 2015;7:763-83.
2. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
3. Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 2015;16:e165-72.
4. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28.
5. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
6. Cooke DT, Gandara DR, Goodwin NC, Calhoun RF, Lara PN Jr, Mack PC, et al. Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer. J Thorac Cardiovasc Surg 2014;148:36-40.